FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
LONDON, Nov. 30, 2017 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 10,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 106.85 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 135,787 Ordinary Shares, representing 0.13% of the Company’s issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| a) | Name | David Ebsworth | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Non-Executive Chairman | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Verona Pharma plc | ||
| b) | LEI | 213800EVI6O6J3TIAL06 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 5 pence each | ||
| Identification code | GB00BYW2KH80 | |||
| b) | Nature of the transaction | David Ebsworth purchased 10,000 Ordinary Shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| 106.85 pence per Ordinary Share | 10,000 Ordinary Shares | |||
| d) | Aggregated information | N/A | ||
| - Aggregated volume | ||||
| - Price | ||||
| e) | Date of the transaction | 29 November 2017 | ||
| f) | Place of the transaction | London Stock Exchange, AIM | ||
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 [email protected] |
| Stewart Wallace / Jonathan Senior / Ben Maddison |
